Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033669 | 0.93 | CCR2 (0.55) | CCR2CCR5TNK2IRAK4 | |
| SCHEMBL15033817 | 0.93 | CCR2 (0.55) | CCR2CCR5TNK2IRAK4 | |
| SCHEMBL15033802 | 0.93 | CCR2 (0.55) | CCR2CCR5TNK2IRAK4 | |
| SCHEMBL15033803 | 0.92 | CCR2 (0.47) | CCR2CCR5 | |
| SCHEMBL15033673 | 0.92 | CCR2 (0.47) | CCR2CCR5 | |
| SCHEMBL15033716 | 0.83 | CCR2 (0.46) | CCR2CCR5TNK2IRAK4LCK | |
| SCHEMBL20039984 | 0.82 | CCR2 (0.46) | CCR2CCR5TNK2HPGD | |
| SCHEMBL24176496 | 0.81 | CCR2 (0.47) | CCR2CCR5TNK2LCKHPGD | |
| SCHEMBL18924971 | 0.81 | CCR2 (0.47) | CCR2CCR5TNK2LCKHPGD | |
| SCHEMBL15849345 | 0.81 | CCR2 (0.69) | CCR2CCR5TNK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CCR2 1/4885CCR5 6/4885TNK2 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.